Hit hard and remove treatment – this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave
-
Published:2024-03
Issue:3
Volume:35
Page:245-247
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Funder
Vetenskapsrådet
Sjöbergstiftelsen
Cancerfonden
Reference14 articles.
1. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial;Ferdinandus;Ann Oncol,2024
2. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group;Borchmann;Lancet,2017
3. Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study;Glimelius;J Cancer Surviv,2015
4. Hodgkin lymphoma;Connors;Nat Rev Dis Primers,2020
5. Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma;Evens;Blood,2021